Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
This is a 2 part study of the safety, pharmacokinetics and pharmacodynamics of MK-6325 in
HCV-infected participants. Part I of the study will be for Genotype (GT) 1 HCV-infected
participants who will be randomized to receive either MK-6325 or placebo. If the drug is
shown to be safe and efficacious in Part I, Part II will enroll GT 3 HCV-infected
participants who will be randomized to receive either MK-6325 or placebo.